Abstract
Pretreatment with interleukin (IL)-10 inhibited the release of growth-related oncogene GRO-alpha but not of epithelial-cell derived neutrophil activating protein (ENA)-78, after injection of lipopolysaccharide (LPS) into healthy humans. In vitro, IL-10 dose-dependently attenuated LPS-induced release of both GRO-alpha and ENA-78 in whole blood and in cultures of isolated polymorphonuclear and mononuclear cells.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Chemokine CXCL1
-
Chemokine CXCL5
-
Chemokines, CXC / analysis*
-
Chemotactic Factors / analysis*
-
Double-Blind Method
-
Endotoxemia / chemically induced
-
Endotoxemia / drug therapy*
-
Endotoxemia / immunology
-
Growth Substances / analysis*
-
Humans
-
Injections, Intravenous
-
Intercellular Signaling Peptides and Proteins*
-
Interleukin-10 / therapeutic use*
-
Interleukin-8 / analogs & derivatives
-
Interleukin-8 / analysis*
-
Leukocytes, Mononuclear / immunology
-
Lipopolysaccharides / antagonists & inhibitors
-
Male
-
Neutrophils / immunology
Substances
-
CXCL1 protein, human
-
CXCL5 protein, human
-
Chemokine CXCL1
-
Chemokine CXCL5
-
Chemokines, CXC
-
Chemotactic Factors
-
Growth Substances
-
Intercellular Signaling Peptides and Proteins
-
Interleukin-8
-
Lipopolysaccharides
-
Interleukin-10